Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622683 | 0.90 | CYP51A1 (0.46) | CYP51A1ADRB3ADRB2ADRB1NAMPT | |
| SCHEMBL7122416 | 0.87 | ADRB3 (0.46) | ADRB3BACE1 | |
| SCHEMBL7694265 | 0.87 | ADRB3 (0.46) | ADRB3BACE1 | |
| SCHEMBL7122412 | 0.87 | ADRB3 (0.46) | ADRB3BACE1 | |
| SCHEMBL30605113 | 0.86 | CYP51A1 (0.63) | CYP51A1ADRB3BACE1 | |
| SCHEMBL26177749 | 0.86 | CYP51A1 (0.63) | CYP51A1ADRB3BACE1 | |
| SCHEMBL30605122 | 0.85 | CYP51A1 (0.62) | CYP51A1ADRB3ADRB2ADRB1NAMPT | |
| SCHEMBL26177748 | 0.85 | CYP51A1 (0.62) | CYP51A1ADRB3ADRB2ADRB1NAMPT | |
| SCHEMBL6388756 | 0.85 | ADRB3 (0.46) | CYP51A1ADRB3NAMPT | |
| SCHEMBL6388761 | 0.85 | ADRB3 (0.46) | CYP51A1ADRB3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291491-B1 | TREATMENT OF TYPE II DIABETES AND OBESITY; ANTIDEPRESSANTS; DECREASE GUT MOTILITY. | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |